Author

Mengying Li

Simcere Pharmaceutical (China)ORCID 0000-0002-3713-1683Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

Chunxia Ao· 1 shared Fan YangiD· 1 shared Fanyu Kong· 1 shared Feng ZhouiD· 1 shared Gang Liu· 1 shared Jiajia LiiD· 1 shared Jiamo Zhang· 1 shared Jing DaiiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chunxia Ao

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinAI: a general bioinformatic framework for multi-level transcriptomic data analysis using multiple semi-agents

Mintian Cui, Shixi Wang, Fan Yang, Yifei Wang, Fanyu Kong, Ni Kong, Mengying Li, Xiaoyue Qiao, Zhen Xu, Ziyu Yan, Yu Yan, Jiamo Zhang, Kun Chen

BioinAI introduces a framework with algorithms DeepAdvancer and stNiche to analyze transcriptomic data, revealing inflammatory axes and cellular niches across skin conditions.

bioRxiv · Jul 21, 2025 · PreprintBioinformatics

ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors

Lei Jiang, Jiajia Li, Lu Liu, Mengying Li, Wenjing Li, Zhen Li, Shuo Qian, Mingyue Shi, Jing Dai, Chunxia Ao, Ying Qu, Zhengtao Li, Li Zhou, Yang Chen, Xiyuan Wang, , Liting Xue

ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.

bioRxiv · Apr 19, 2025 · PreprintCancer Biology